PapeixCVukusicSCaseyR, et al. Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm2016; 3(6): e297.
2.
ProsperiniLKinkelRPMiravalleAA, et al. Post-natalizumab disease reactivation in multiple sclerosis: Systematic review and meta-analysis. Ther Adv Neurol Disord2019; 12: 837809.
3.
KryskoKMGravesJSDobsonR, et al. Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord2020; 13: 936166.
4.
HellwigKGoldR. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?Neurology2011; 76: 1362–1363; author reply 1363.
5.
LarochelleCMetzILécuyerMA, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler2017; 23(1): 72–81.
6.
DemortiereSRicoAMaaroufA, et al. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Mult Scler J2021; 27(5): 712–718.
7.
SimisterNE. Placental transport of immunoglobulin G. Vaccine2003; 21: 3365–3369.
8.
HaghikiaALanger-GouldARellensmannG, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol2014; 71: 891–895.
9.
CipleaAIHellwigK. Exposure to natalizumab during pregnancy and lactation is safe: Commentary. Mult Scler2020; 26(8): 892–893.
10.
PortaccioEMoiolaLMartinelliV, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology2018; 90: e832–e839.
11.
CipleaAILanger-GouldAde VriesA, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm2020; 7: e723.
